title: Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
authors.affiliation: Aflac Cancer Center and Blood Disorders Service, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA. Marianne.McPherson@choa.org
authors.forename: M E
authors.initials: ME
authors.lastname: McPherson
authors.forename: D
authors.initials: D
authors.lastname: Hutcherson
authors.forename: E
authors.initials: E
authors.lastname: Olson
authors.forename: A E
authors.initials: AE
authors.lastname: Haight
authors.forename: J
authors.initials: J
authors.lastname: Horan
authors.forename: K-Y
authors.initials: KY
authors.lastname: Chiang
mesh_terms: D000293:Adolescent; D000755:Anemia, Sickle Cell / Q000628:therapy*; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002066:Busulfan / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D046528:Chimerism / Q000187:drug effects; D016903:Drug Monitoring / Q000009:adverse effects; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D008297:Male; D019653:Myeloablative Agonists / Q000009:adverse effects* / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012189:Retrospective Studies; D035781:Siblings; D016019:Survival Analysis; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects
chemical_list: D019653:Myeloablative Agonists; D002066:Busulfan